The inhibition of adjuvant disease in rats by the interferon-inducing agent pyran copolymer

✍ Scribed by By M. A. Kapusta; J. Mendelson

• Publisher: John Wiley and Sons
• Year: 1969
• Tongue: English
• Weight: 643 KB
• Volume: 12
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.1780120502

✦ Synopsis

The effect of pyran copolymer, a synthetic polyanionic interferon inducer, was studied in adjuvant-induced disease in rats. This agent was shown to induce interferon in Sprague-Dawley and CD@F rats and to inhibit adjuvant-induced arthritis in both species of rats. Splenomegaly was inhibited in CD@F rats. Based on the time at which single injections ATS, given a single intracutaneous in-R jection of Freunds adjuvant, may develop polyarthritis, periostitis, and tendinitis.* Adjuvant disease is also characterized by splenomegaly.2 Less frequent findings include inflammation of various portions of the eye, skin, and urogenital t r a ~t . ~. ~ Because of the similarity of the animal disease to rheumatoid arthritis and Reiter's syndrome in man, there is great interest in were most effective, pyran did not seem to have an antiinflammatory effect and its action was different from antilymphocyte serum. These data open the question of the role of a virus or virus-like microorganism in the pathogenesis of adjuvant disease. A hypothesis reconciling immune participation in this disease with the role of a possible infectious agent is presented.

this animal model since it may provide insights into the human disease^.^ Adjuvant disease is believed to be due to a form of delayed hypersensitivity reaction to mycobacterial antigen( s ) because: (1) the induction of tolerance to mycobacterial antigen( s ) in the neonatal period can inhibit subsequent production of the dis-ease4v5; (2) there is a characteristic 10-14 day latent period between induction and